Trial Profile
An Initial Double-Blind, Placebo-Controlled Two-Dose Crossover Study of AZD7325 in Adults With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 7325 (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 01 Feb 2021 Status changed from recruiting to completed.
- 26 Feb 2020 Planned End Date changed from 1 Jul 2018 to 1 Oct 2020.
- 26 Feb 2020 Planned primary completion date changed from 1 May 2018 to 1 Jul 2020.